Supervised lifestyle intervention from a medical professional may help maximize fat loss and minimize muscle tissue loss in people taking the potent weight loss drugs.

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

GLP-1RA medications in preadolescents and adolescents were concentrated among those with diabetes, obesity, mood disorders, and anxiety.

Presentation Title: Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass and Physical Function in Older Patients Receiving Semaglutide for Weight Loss Date: April 30, 2025 Start time: 12:30 ...

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

From 2008-2011 to 2020-2023, there was an increase in the prevalence of obesity among youth and adults with T1D, and GLP-1 RA prescriptions also increased.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

As a large proportion of people taking medications like Mounjaro, Ozempic and Wegovy for weight loss report consuming less processed foods and soda, researchers say food and beverage companies are ...

Shelf-stable vaccine patch maker Vaxess Technologies announced today that it received an additional $9 million in funding.

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Cade Shadbolt, from the University of Melbourne in Australia, and colleagues examined data from the Medical Expenditure Panel Survey Household Component from 2018 to 2022 to examine GLP-1 RA use ...